Top

Published in:

25-02-2022 | Obesity | Original Article

Relation of adipose tissue and skeletal muscle FKBP5 expression with insulin sensitivity and the regulation of FKBP5 by insulin and free fatty acids

Authors: Marek Strączkowski, Magdalena Stefanowicz, Natalia Matulewicz, Agnieszka Nikołajuk, Monika Karczewska-Kupczewska

Published in: Endocrine | Issue 3/2022

Abstract

Purpose

Recent studies suggest that FK506 binding protein 51 (FKBP51), a negative regulator of glucocorticoid response, encoded by FKBP5, may influence insulin action. The aim of the present study was to assess the relationship between subcutaneous adipose tissue (AT) and skeletal muscle FKBP5 expression in relation to insulin sensitivity in healthy individuals and to study its regulation by insulin and circulating free fatty acid (FFA) elevation.

Methods

The study group comprised 96 male subjects, 49 normal-weight and 47 overweight/obese. Hyperinsulinemic clamp, subcutaneous AT and skeletal muscle biopsies were performed. In a subgroup of 20 subjects, two 6 h clamps were performed, with and without Intralipid/heparin infusion, and tissue biopsies were obtained before and after each clamp.

Results

AT FKBP5 expression was lower in overweight/obese individuals in comparison with normal-weight individuals (p = 0.004). Muscle FKBP5 expression did not differ between the groups, however, it was inversely related to insulin sensitivity (r = −0.32, p = 0.002). FKBP5 expression decreased in AT (p = 0.003) and increased in muscle (p < 0.0001) after insulin infusion. Intralipid/heparin diminished insulin-induced increase in muscle FKBP5.

Conclusion

Our data show that lower AT FKBP5 expression is related to obesity, whereas muscle FKBP5 expression is associated with insulin resistance. AT and muscle FKBP5 expression is differentially regulated by insulin.

M.P. Czech, Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804–814 (2017). https://doi.org/10.1038/nm.4350CrossRefPubMedPubMedCentral

B.E. Wisse, The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792–2800 (2004). https://doi.org/10.1097/01.ASN.0000141966.69934.21CrossRefPubMed

E. Ferrannini, O. Bjorkman, G.A. Reichard Jr., A. Pilo, M. Olsson, J. Wahren, R.A. DeFronzo, The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes 34, 580–588 (1985). https://doi.org/10.2337/diab.34.6.580CrossRefPubMed

E.B. Geer, J. Islam, C. Buettner, Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol. Metab. Clin. North Am. 43, 75–102 (2014). https://doi.org/10.1016/j.ecl.2013.10.005CrossRefPubMedPubMedCentral

M. Kumari, T. Chandola, E. Brunner, M. Kivimaki, A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J. Clin. Endocrinol. Metab. 95, 4415–4423 (2010). https://doi.org/10.1210/jc.2009-2105CrossRefPubMedPubMedCentral

M. Schorr, E.A. Lawson, L.E. Dichtel, A. Klibanski, K.K. Miller, Cortisol measures across the weight spectrum. J. Clin. Endocrinol. Metab. 100, 3313–3321 (2015). https://doi.org/10.1210/JC.2015-2078CrossRefPubMedPubMedCentral

R.A. Lee, C.A. Harris, J.C. Wang, Glucocorticoid receptor and adipocyte biology. Nucl. Receptor Res. 5, 101373 (2018). https://doi.org/10.32527/2018/101373CrossRefPubMedPubMedCentral

L.L. Gathercole, S.A. Morgan, I.J. Bujalska, D. Hauton, P.M. Stewart, J.W. Tomlinson, Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PloS. One 6, e26223 (2011). https://doi.org/10.1371/journal.pone.0026223CrossRefPubMedPubMedCentral

J. Burén, H.X. Liu, J. Jensen, J.W. Eriksson, Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur. J. Endocrinol. 146, 419–429 (2002). https://doi.org/10.1530/eje.0.1460419CrossRefPubMed

10.

M. Lundgren, J. Burén, T. Ruge, T. Myrnäs, J.W. Eriksson, Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 89, 2989–2997 (2004). https://doi.org/10.1210/jc.2003-031157CrossRefPubMed

11.

L.L. Gathercole, I.J. Bujalska, P.M. Stewart, J.W. Tomlinson, Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J. Clin. Endocrinol. Metab. 92, 4332–4339 (2007). https://doi.org/10.1210/jc.2007-1399CrossRefPubMed

12.

T. Ratajczak, C. Cluning, B.K. Ward, Steroid receptor-associated immunophilins: a gateway to steroid signaling. Clin. Biochem. Rev. 36, 31–52 (2015)PubMedPubMedCentral

13.

A.S. Zannas, T. Wiechmann, N.C. Gassen, E.B. Binder, Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology 41, 261–274 (2016). https://doi.org/10.1038/npp.2015.235CrossRefPubMed

14.

G. Balsevich, A. Uribe, K.V. Wagner, J. Hartmann, S. Santarelli, C. Labermaier, M.V. Schmidt, Interplay between diet-induced obesity and chronic stress in mice: potential role of FKBP51. J. Endocrinol. 222, 15–26 (2014). https://doi.org/10.1530/JOE-14-0129CrossRefPubMed

15.

L.A. Stechschulte, B. Qiu, M. Warrier, T.D. Hinds Jr., M. Zhang, H. Gu, Y. Xu, S.S. Khuder, L. Russo, S.M. Najjar, B. Lecka-Czernik, W. Yong, E.R. Sanchez, FKBP51 null mice are resistant to diet-induced obesity and the pparγ agonist rosiglitazone. Endocrinology 157, 3888–3900 (2016). https://doi.org/10.1210/en.2015-1996CrossRefPubMedPubMedCentral

16.

G. Balsevich, A.S. Häusl, C.W. Meyer, S. Karamihalev, X. Feng, M.L. Pöhlmann, C. Dournes, A. Uribe-Marino, S. Santarelli, C. Labermaier, K. Hafner, T. Mao, M. Breitsamer, M. Theodoropoulou, C. Namendorf, M. Uhr, M. Paez-Pereda, G. Winter, F. Hausch, A. Chen, M.H. Tschöp, T. Rein, N.C. Gassen, M.V. Schmidt, Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nat. Commun. 8, 1725 (2017). https://doi.org/10.1038/s41467-017-01783-yCrossRefPubMedPubMedCentral

17.

A.I. Su, T. Wiltshire, S. Batalov, H. Lapp, K.A. Ching, D. Block, J. Zhang, R. Soden, M. Hayakawa, G. Kreiman, M.P. Cooke, J.R. Walker, J.B. Hogenesch, A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101, 6062–6067 (2004). https://doi.org/10.1073/pnas.0400782101CrossRefPubMedPubMedCentral

18.

L.A. Stechschulte, T.D. Hinds Jr., S.S. Khuder, W. Shou, S.M. Najjar, E.R. Sanchez, FKBP51 controls cellular adipogenesis through p38 kinase-mediated phosphorylation of GRα and PPARγ. Mol. Endocrinol. 28, 1265–1275 (2014). https://doi.org/10.1210/me.2014-1022CrossRefPubMedPubMedCentral

19.

M.J. Pereira, J. Palming, M.K. Svensson, M. Rizell, J. Dalenbäck, M. Hammar, T. Fall, C.O. Sidibeh, P.A. Svensson, J.W. Eriksson, FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance. Metabolism 63, 1198–1208 (2014). https://doi.org/10.1016/j.metabol.2014.05.015CrossRefPubMed

20.

C.O. Sidibeh, M.J. Pereira, X.M. Abalo, J. Boersma, G. Skrtic, S. Lundkvist, P. Katsogiannos, P. Hausch, F. Castillejo-López, J.W. C., Eriksson, FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. Endocrine 62, 1161–1128 (2018). https://doi.org/10.1007/s12020-018-1674-5CrossRef

21.

M. Karczewska-Kupczewska, M. Stefanowicz, N. Matulewicz, A. Nikołajuk, M. Strączkowski, Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees of insulin sensitivity. J. Clin. Endocrinol. Metab 101, 3079–3087 (2016). https://doi.org/10.1210/jc.2016-1594CrossRefPubMed

22.

N. Matulewicz, M. Stefanowicz, A. Nikołajuk, M. Karczewska-Kupczewska, Markers of adipogenesis, but not inflammation in adipose tissue, are independently related to insulin sensitivity. J. Clin. Endocrinol. Metab. 102, 3040–3049 (2017). https://doi.org/10.1210/jc.2017-00597CrossRefPubMed

23.

L. Zhang, B. Qiu, T. Wang, J. Wang, M. Liu, Y. Xu, C. Wang, R. Deng, K. Williams, Z. Yang, T. Liang, W. Yong, Loss of FKBP5 impedes adipocyte differentiation under both normoxia and hypoxic stress. Biochem. Biophys. Res. Commun. 485, 761–767 (2017). https://doi.org/10.1080/15548627.2015.1100356CrossRefPubMed

24.

W.C. Yeh, T.K. Li, B.E. Bierer, S.L. McKnight, Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Proc. Natl Acad. Sci. USA 92, 11081–11085 (1995). https://doi.org/10.1073/pnas.92.24.11081CrossRefPubMedPubMedCentral

25.

M. Fichna, I. Krzyśko-Pieczka, M. Żurawek, B. Skowrońska, D. Januszkiewicz-Lewandowska, P. Fichna, FKBP5 polymorphism is associated with insulin resistance in children and adolescents with obesity. Obes. Res. Clin. Pract. 12, 62–70 (2018). https://doi.org/10.1016/j.orcp.2016.11.007CrossRefPubMed

Title: Relation of adipose tissue and skeletal muscle FKBP5 expression with insulin sensitivity and the regulation of FKBP5 by insulin and free fatty acids
Authors: Marek Strączkowski
Magdalena Stefanowicz
Natalia Matulewicz
Agnieszka Nikołajuk
Monika Karczewska-Kupczewska
Publication date: 25-02-2022
Publisher: Springer US
Keywords: Obesity
Obesity
Insulins
Glucocorticoid
Heparin
Overweight
Insulins
Published in: Endocrine / Issue 3/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03018-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relation of adipose tissue and skeletal muscle FKBP5 expression with insulin sensitivity and the regulation of FKBP5 by insulin and free fatty acids

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2022

Body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) e waist body mass index (wBMI): Which is better?

The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors

Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine

Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes

Effect of thyroid function on pre-β1 high-density lipoprotein levels in patients with Graves’ disease undergoing radioiodine treatment

Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page